Introduction {#S5}
============

Deafness is a global public health concern which affects 1 to 3 per 1,000 newborns.^[@R1]^ In more than half of the cases with congenital or prelingual deafness, the cause is genetic and most demonstrate an autosomal recessive inheritance pattern.^[@R1]^ Mutations in 58 different genes have been reported to cause autosomal recessive non-syndromic deafness (ARNSD) (<http://hereditaryhearingloss.org/>).

Except for one relatively common gene, *GJB2* (MIM 121011), most reported mutations are present in only a single or a few families.^[@R2]^ Whole-exome sequencing (WES) allows resequencing of nearly all exons of the protein-coding genes in the genome.^[@R3]^ A growing number of research and clinical diagnostic laboratories are successfully using WES for gene/variant identification, owing to its comprehensive analysis advantages.^[@R4],[@R5]^ In this study, we present the results of WES in a large multiethnic cohort consisting of 160 families with ARNSD that were negative for *GJB2* mutations.

Material and Methods {#S6}
====================

Statement of Ethics {#S7}
-------------------

This study was approved by the University of Miami Institutional Review Board (USA), Ankara University Medical School Ethics Committee (Turkey), Growth and Development Research Ethics Committee (Iran), Bioethics Committee of FFAA (HE-1) in Quito (Ecuador) and the Ethics Committee of National Institute of Rehabilitation (Mexico). A signed informed consent form was obtained from each participant or, in the case of a minor, from parents.

Subjects {#S8}
--------

We included 160 families with at least two members with nonsyndromic sensorineural hearing loss with a pedigree structure suggestive of autosomal recessive inheritance (affected siblings born to unaffected parents with or without parental consanguinity) and *GJB2* mutations were negative. Hearing loss was congenital or prelingual onset with a severity ranging from mild to profound. One hundred and one families from Turkey, fifty-four from Iran, two from Mexico, two from Ecuador and one from Puerto Rico were included. Sensorineural hearing loss was diagnosed via standard audiometry in a sound-proof room according to standard clinical practice. Clinical evaluation of all affected individuals by a geneticist and an otolaryngologist included a thorough physical examination, otoscopy, and ophthalmoscopy. Tandem walking and the Romberg test were used for initial vestibular evaluation with more detailed tests if needed based on symptoms and findings. Laboratory investigation included but was not limited to an EKG, urinalysis, and, when available, a high resolution CT scan of the temporal bone or an MRI to identify inner ear anomalies. DNA was extracted from peripheral leukocytes of each member of the family by standard protocols.

Whole-Exome Sequencing {#S9}
----------------------

Agilent SureSelect Human All Exon 50 Mb versions 3, 4, and 5 (Agilent Technologies Santa Clara, CA) were used for in-solution enrichment of coding exons and flanking intronic sequences following the manufacturer\'s standard protocol. The enriched DNA samples were subjected to standard sample preparation for the HiSeq 2000 instrument (Illumina San Diego, CA). The Illumina CASAVA v1.8 pipeline was used to produce 99 bp sequence reads. BWA^[@R6]^ was used to align sequence reads to the human reference genome (hg19) and variants were called using the GATK (<https://www.broadinstitute.org/gatk/>) software package.^[@R7]^ All single nucleotide variants (SNVs) and insertion/deletions (INDELs) were submitted to SeattleSeq137 for further characterization and annotation. Sanger sequencing was used for confirmation and segregation of the variants in each family.

Bioinformatics Analysis {#S10}
-----------------------

We analyzed WES data using our in house tool (<https://genomics.med.miami.edu>). Our workflow is seen in [Figure 1](#F1){ref-type="fig"}. The analysis started with QC checks including the coverage and average read depth of targeted regions, numbers of variants in different categories, and quality scores. All variants were annotated and categorized into known and novel variants. As previously recommended, we filtered variants based on minor allele frequency of \<0.005 in dbSNP141.^[@R8]^ We also filtered out variants that are present in \>10 samples in our internal database of \>3,000 exomes from European, Asian, and American ancestries that includes Turkish, Iranian, Mexican, Ecuadorian, and Puerto Rican samples ([Figure 1](#F1){ref-type="fig"}). Autosomal recessive inheritance with both homozygous and compound heterozygous inheritance models, and a genotype quality (GQ) score \>35 for the variant quality were chosen. Missense, nonsense, splice site, in-frame INDEL and frame-shift INDELs in the known ARNSD genes ([supplementary data](#SD1){ref-type="supplementary-material"}) were selected. Missense variants that remained after these filters were later analyzed for presence in the Human Gene Mutation Database (HGMD) ([www.hgmd.cf.ac.uk](http://www.hgmd.cf.ac.uk)) and having a pathogenic prediction score at least in two of the following tools: PolyPhen2^[@R9]^, SIFT^[@R10]^, MutationAssessor^[@R11]^, and MutationTaster^[@R12]^. Finally, we used CoNIFER^[@R13]^ (Copy Number Inference From Exome Reads) and XHMM^[@R14]^ (eXome-Hidden Markov Model) to detect CNVs.^[@R15]^ After this filtering, only those variants co-segregated with the phenotype in the entire family was considered pathogenic.

Results {#S11}
=======

On average, each exome had 99%, 95% and 88% of mappable bases of the Gencode defined exome represented by coverage of 1X, 5X and 10X reads, respectively. Average coverage of the mappable bases for the 58 known ARNSD genes (exons and the first and last 20 bps of introns) were 99%, 95%, 87% for the 1X, 5X, 10X reads, respectively.

We detected pathogenic or likely pathogenic variants that can explain ARNSD in 90 (56%) families. All identified variants co-segregated with deafness as an autosomal recesive trait. 54% of the mutations were not previously reported in HGMD. Mutations were identified in 31 ARNSD genes. The genes with mutations identified in at least three families are *MYO15A* (MIM 602666) *(13%), MYO7A* (MIM 276903) *(11%), SLC26A4* (MIM 605646) *(10%), TMPRSS3* (MIM 605551) *(9%), TMC1* (MIM 606706) *(8%), ILDR1* (MIM 609739) *(6%), CDH23* (MIM 605516) *(4%), OTOF* (MIM 603681) *(4%), PCDH15* (MIM 605514) *(3%)*, and *TMIE* (MIM 607723) *(3%)*. During the course of this study we reported mutations in *OTOGL* (MIM 614925) and *FAM65B* (MIM 611410) as novel causes of ARNSD^[@R16],[@R17]^ ([Figure 1](#F1){ref-type="fig"})([Table 1](#T1){ref-type="table"}).

Discussion {#S12}
==========

Identifying causative variants in ARNSD is challenging because of (1) the extreme genetic heterogeneity of ARNSD; (2) the presence of different categories of genetic variants such as SNVs, INDELs and CNVs; (3) the presence of a high proportion of non-recurrent mutations and (4) the variability in mutation frequencies in individual ARNSD genes across ethnicities.^[@R18]^ Consequently, we performed a comprehensive analysis to detect pathogenic SNVs, INDELs and CNVs in the ARNSD genes.

Targeted resequencing allows identification of mutations in the interested gene sets. Recent studies pioneered by Shearer et al. have shown the effectiveness of the targeted resequencing of deafness genes.^[@R8],[@R19]^ An advantage of the targeted resequencing over WES is having better coverage with higher depth and significantly lowered costs, which is suitable for clinical diagnostic labs. However, a main limitation of the targeted sequencing is the need for revalidation of the panel after adding each new gene. In contrast, many laboratories around the world offer WES as a diagnostic tool requiring validation only when a new WES version is introduced. Our analysis using three different versions of an exome capture kit during the four year period shows that the depth of coverage of WES has improved to reliably identify most mutations in known ARNSD genes ([Figure 2](#F2){ref-type="fig"}) ([Table S1](#SD1){ref-type="supplementary-material"} and [Table S4](#SD1){ref-type="supplementary-material"}). Recently developed WES approaches provide more coverage for genes that are known to cause Mendelian disease. They are expected to cover deafness genes more efficiently. In addition, adding in baits to improve coverage over poorly covered regions may be considered if a better coverage is desired. It was recently shown via targeted sequencing that CNVs are a common cause of deafness.^[@R20]^ While CNV analysis of the WES data is being still optimized for clinical usage, we integrated two currently available tools, XHMM and CoNIFER into our WES analysis pipeline and identified large *OTOA* (MIM 607038), *STRC* (MIM 606440) and *PCDH15* (exon 27-28) homozygous deletions in our cohort, supporting a significant role of CNVs to in deafness etiology.

In this study after excluding *GJB2* mutations we detected pathogenic variants in the known ARNSD genes in 56% of the studied families. The advantage of this study is to have large multiplex autosomal recessive families (including affected and unaffected children) that can be tested for co-segregation of all variants. While we identified more novel variants than those reported in [Table 1](#T1){ref-type="table"} through WES, only those variants co-segregated in the family with deafness were considered pathogenic. Similarly heterozygous variants didn\'t explain the phenotype since they did not co-segregate with deafness and were not included. WES facilitates the cataloguing of mutations in different populations. Population characteristics such as the rate of consanguineous marriages may affect the distribution of deafness mutations in different populations. As expected, the vast majority of Turkish and Iranian probands from consanguineous marriages are homozygous for the pathogenic variants ([Table 2](#T2){ref-type="table"}). However, there is a marked difference between the rates of solved families in Turkey (73%) vs. Iran (24%) ([Figure 3](#F3){ref-type="fig"}). As seen in [figure 3](#F3){ref-type="fig"}, the distribution of genes is also different between the two countries. In our study, the top five genes explain 39 out of 101 families (39%) in Turkey, while only 10 out of 54 families (19%) in Iran. Moreover, our analysis of the WES data in the unsolved Iranian families shows that there are no common mutations in genes that are not known to be deafness genes (data not shown). Unless there are common mutations in regions that are not well covered by WES, our data suggest that many rare genes are responsible for the majority of hereditary deafness in the Iranian cohort. It is likely that there are undetected rare variants specific to certain ethnicities in Iran.^[@R21]^ Another advantage of WES is to allow surveying of mutations for founder effects. We detected *TMIE* c.250C\>T (p.R84W) in three unrelated Turkish families, which all shared a flanking haplotype as noted previously.^[@R22]^ Furthermore *MYO15A, MYO7A, SLC26A4, TMPRSS3, ILDR1, OTOF, ESRRB* (MIM 602167) and *GIPC3* (MIM 608792) genes had recurrent mutations with shared haplotypes indicating founder effects ([Table S2](#SD1){ref-type="supplementary-material"}).

There is no correlation between the size of transcript and number of mutant alleles ([Table S3](#SD1){ref-type="supplementary-material"}). There may be some deafness genes that are more prone to have mutations. Founder effects appear to play a role because some small genes such as *TMIE*, *ESRRB*, and *GIPC3* ranked high in mutation frequency because of founder mutations. Some discrepancy between the size of a gene and number of mutations can be explained by the fact that only certain mutations cause nonsyndromic deafness for some genes. For instance, *CDH23*, *PCDH15*, *MYO7A* are big genes but many mutations in those genes cause Usher syndrome (MIM 276900) instead of ARNSD. An interesting example is *TMC1* that ranks the 20th based on size but the 5th for mutation frequency. Nonsyndromic deafness is the only phenotype caused by *TMC1* mutations and none of the *TMC1* mutations are recurrent in our cohort. These may suggest that *TMC1* is relatively more prone to have *de novo* mutations or it is a highly conserved gene and its variants are rarely tolerated.

In conclusion, WES is a an effective tool for identifying pathogenic SNVs, INDELs and CNVs simultaneously in ARNSD genes and provides further analysis of the unsolved families for novel gene discovery. Identification of two novel ARNSD genes^[@R16],[@R17]^ during the course of this study testifies its power.

Supplementary Material {#S13}
======================
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###### Mutations identified in known ARNSD genes[\*](#TFN1){ref-type="table-fn"}

  Family ID        Country of origin   Genotype         cDNA                    Protein           NM Transcript                Gene        Reference
  ---------------- ------------------- ---------------- ----------------------- ----------------- ---------------------------- ----------- ----------------------------
  **543**          Turkey              Homozygous       c.4441T\>C              p.S1481P          NM_016239.3                  MYO15A      (Cengiz 2010)^[@R23]^
  **724**          Turkey              Homozygous       c.4652C\>A              p.A1551D          NM_016239.3                  MYO15A      (Diaz-Horta 2012)^[@R4]^
  **765**          Turkey              Homozygous       c.4273C\>T              p.Q1425X          NM_016239.3                  MYO15A      (Diaz-Horta 2012)^[@R4]^
  **723**          Turkey              Homozygous       c.8307_8309delGGA       p.E2770del        NM_016239.3                  MYO15A      Novel
  **795**          Turkey              Homozygous       c.5808_5814delCCGTGGC   p.R1937TfsX10     NM_016239.3                  MYO15A      (Cengiz 2010)^[@R23]^
  **793**          Turkey              Homozygous       c.5808_5814delCCGTGGC   p.R1937TfsX10     NM_016239.3                  MYO15A      (Cengiz 2010)^[@R23]^
  **1209**         *Puerto Rico*       *Heterozygous*   *c.7226delC*            *p.P2409QfsX8*    *NM_016239.3*                *MYO15A*    *Novel*
  *Heterozygous*   *c.9620G\>A*        *p.R3207H*       *NM_016239.3*           *MYO15A*          *Novel*                                  
  **1083**         Turkey              Homozygous       c.5183T\>C              p.L1728P          NM_016239.3                  MYO15A      Novel
  **1332**         Turkey              Homozygous       c.10361delT             p.V3454GfsX5      NM_016239.3                  MYO15A      Novel
  **489**          Turkey              Homozygous       c.5286_5287delTC        p.R1763AfsX45     NM_016239.3                  MYO15A      Novel
  **1023**         Iran                Homozygous       c.8638_8641delCCTG      p.P2880RfsX19     NM_016239.3                  MYO15A      Novel
  **862**          *Turkey*            *Heterozygous*   *c.7894G\>T*            *p.V2632L*        *NM_016239.3*                *MYO15A*    *Novel*
  *Heterozygous*   *c.5133+1G\>A*      *splice*         *NM_016239.3*           *MYO15A*          *Novel*                                  
  **974**          Iran                Homozygous       c.6487G\>A              p.G2163S          NM_000260.3                  MYO7A       (Janecke 1999)^[@R24]^
  **1391**         Turkey              Homozygous       c.6487G\>A              p.G2163S          NM_000260.3                  MYO7A       (Janecke 1999)^[@R24]^
  **435**          Turkey              Homozygous       c.3935T\>C              p.L1312P          NM_000260.3                  MYO7A       Novel
  **472**          Turkey              Homozygous       c.1556G\>T              p.G519V           NM_000260.3                  MYO7A       Novel
  **1370**         Turkey              Homozygous       c.722G\>A               p.R241H           NM_000260.3                  MYO7A       (Cremers 2007)^[@R25]^
  **432**          Turkey              Homozygous       c.5362_5363delAG        p.R1788DfsX13     NM_000260.3                  MYO7A       Novel
  **637**          *Turkey*            *Heterozygous*   *c.5838delT*            *p.F1946LfsX24*   *NM_000260.3*                *MYO7A*     *Novel*
  *Heterozygous*   *c.5573T\>C*        *p.L1858P*       *NM_000260.3*           *MYO7A*           *(Bharadwaj 2000)*^[@R26]^               
  **996**          Iran                Homozygous       c.5785C\>T              p.Q1929X          NM_000260.3                  MYO7A       Novel
  **1019**         Iran                Homozygous       c.1708C\>T              p.R570X           NM_000260.3                  MYO7A       (Yoshimura 2014)^[@R27]^
  **1404**         *Turkey*            *Heterozygous*   *c.1708C\>T*            *p.R570X*         *NM_000260.3*                *MYO7A*     *(Yoshimura 2014)*^[@R27]^
  *Heterozygous*   *c.6025G\>A*        *p.A2009T*       *NM_000260.3*           *MYO7A*           *Novel*                                  
  **786**          Turkey              Homozygous       c.1001G\>T              p.G334V           NM_000441.1                  SLC26A4     (Landa 2013)^[@R28]^
  **634**          Turkey              Homozygous       c.1001G\>T              p.G334V           NM_000441.1                  SLC26A4     (Landa 2013)^[@R28]^
  **1418**         Turkey              Homozygous       c.1061T\>C              p.F354S           NM_000441.1                  SLC26A4     (Blons 2004)^[@R29]^
  **238**          Turkey              Homozygous       c.1226G\>A              p.R409H           NM_000441.1                  SLC26A4     (Van hauwe 1998)^[@R30]^
  **973**          Iran                Homozygous       c.1334T\>G              p.L445W           NM_000441.1                  SLC26A4     (Van hauwe 1998)^[@R30]^
  **905**          Turkey              Homozygous       c.2168A\>G              p.H723R           NM_000441.1                  SLC26A4     (Van hauwe 1998)^[@R30]^
  **1417**         *Turkey*            *Heterozygous*   *c.665G\>A*             *p.G222D*         *NM_000441.1*                *SLC26A4*   *Novel*
  *Heterozygous*   *c.1198delT*        *p.C400VfsX32*   *NM_000441.1*           *SLC26A4*         *Novel*                                  
  **1346**         Turkey              Homozygous       c.919-2A\>G             splice            NM_000441.1                  SLC26A4     (Coucke 1999)^[@R31]^
  **1321**         Turkey              Homozygous       c.1198delT              p.C400VfsX32      NM_000441.1                  SLC26A4     Novel
  **395**          Turkey              Homozygous       c.36dupC                p.F13LfsX10       NM_024022.2                  TMPRSS3     (Diaz-Horta 2012)^[@R4]^
  **777**          Turkey              Homozygous       c.913A\>T               p.I305F           NM_024022.2                  TMPRSS3     Novel
  **674**          Turkey              Homozygous       c.271C\>T               p.R91X            NM_024022.2                  TMPRSS3     Novel
  **629**          Turkey              Homozygous       c.399G\>C               p.W133C           NM_024022.2                  TMPRSS3     Novel
  **1368**         Turkey              Homozygous       c.1126G\>A              p.G376S           NM_024022.2                  TMPRSS3     Novel
  **1410**         Turkey              Homozygous       c.436G\>A               p.G146S           NM_024022.2                  TMPRSS3     Novel
  **910**          Turkey              Homozygous       c.616G\>T               p.A206S           NM_024022.2                  TMPRSS3     Novel
  **633**          Turkey              Homozygous       c.616G\>T               p.A206S           NM_024022.2                  TMPRSS3     Novel
  **52**           Turkey              Homozygous       c.1589_1590CT           p.S530X           NM_138691.2                  TMC1        (Hildebrand 2010)^[@R32]^
  **123**          Turkey              Homozygous       c.1080_1084delGATCA     p.R362PfsX6       NM_138691.2                  TMC1        Novel
  **662**          Turkey              Homozygous       c.2050G\>A              p.D684N           NM_138691.2                  TMC1        Novel
  **1268**         *Ecuador*           *Heterozygous*   *c.1718T\>A*            *p.I573N*         *NM_138691.2*                *TMC1*      *Novel*
  *Heterozygous*   *c.2130-1delG*      *splice*         *NM_138691.2*           *TMC1*            *Novel*                                  
  **911**          Turkey              Homozygous       c.1534C\>T              p.R512X           NM_138691.2                  TMC1        (Kurima 2002)^[@R33]^
  **490**          Turkey              Homozygous       c.1959C\>G              p.Y653X           NM_138691.2                  TMC1        Novel
  **393**          *Turkey*            *Heterozygous*   *c.63+2T\>A*            *splice*          *NM_138691.2*                *TMC1*      *(Duman 2011)*^[@R18]^
  *Heterozygous*   *c.236+1G\>A*       *splice*         *NM_138691.2*           *TMC1*            *(Duman 2011)*^[@R18]^                   
  **988**          Iran                Homozygous       c.3215C\>A              p.A1072D          NM_022124.5                  CDH23       (Duman 2011)^[@R18]^
  **1165**         *Mexico*            *Heterozygous*   *c.2959G\>A*            *p.D987N*         *NM_022124.5*                *CDH23*     *Novel*
  *Heterozygous*   *c.3628C\>T*        *p.Q1210X*       *NM_022124.5*           *CDH23*           *Novel*                                  
  **1015**         Iran                Homozygous       c.5851G\>A              p.D1951N          NM_022124.5                  CDH23       Novel
  **1032**         *Iran*              *Heterozygous*   *c.7822C\>T*            *p.R2608C*        *NM_022124.5*                *CDH23*     *Novel*
  *Heterozygous*   *c.8120C\>T*        *p.P2707L*       *NM_022124.5*           *CDH23*           *Novel*                                  
  **968**          Iran                Homozygous       c.820C\>T               p.Q274X           NM_001199799.1               ILDR1       (Diaz-Horta 2012)^[@R4]^
  **800**          Turkey              Homozygous       c.942C\>A               p.C314X           NM_001199799.1               ILDR1       Novel
  **799**          Turkey              Homozygous       c.942C\>A               p.C314X           NM_001199799.1               ILDR1       Novel
  **782**          Turkey              Homozygous       c.942C\>A               p.C314X           NM_001199799.1               ILDR1       Novel
  **969**          Iran                Homozygous       c.82delG                p.V28SfsX31       NM_001199799.1               ILDR1       Novel
  **1297**         Turkey              Homozygous       c.5431A\>T              p.K1811X          NM_194248.2                  OTOF        (Romanos 2009)^[@R34]^
  **98**           Turkey              Homozygous       c.5431A\>T              p.K1811X          NM_194248.2                  OTOF        (Romanos 2009)^[@R34]^
  **1398**         Turkey              Homozygous       c.3679C\>T              p.R1227X          NM_194248.2                  OTOF        Novel
  **909**          Turkey              Homozygous       c.765G\>C               p.Q255H           NM_194248.2                  OTOF        (Rodriguez 2008)^[@R35]^
  **725**          Turkey              Homozygous       c.3918T\>G              p.C1306W          NM_033056.3                  PCDH15      Novel
  **1238**         Turkey              Homozygous       CNV                     CNV               NM_033056.3                  PCDH15      Novel
  **1044**         Iran                Homozygous       c.3101G\>A              p.R1034H          NM_033056.3                  PCDH15      Novel
  **1369**         Turkey              Homozygous       c.250C\>T               p.R84W            NM_147196.2                  TMIE        (Naz 2002)^[@R36]^
  **1354**         Turkey              Homozygous       c.250C\>T               p.R84W            NM_147196.2                  TMIE        (Naz 2002)^[@R36]^
  **1402**         Turkey              Homozygous       c.250C\>T               p.R84W            NM_147196.2                  TMIE        (Naz 2002)^[@R36]^
  **1239**         Turkey              Homozygous       c.490-1G\>T             splice            NM_016366.2                  CABP2       Novel
  **1366**         Turkey              Homozygous       c.1018G\>T              p.E340X           NM_004452.3                  ESRRB       Novel
  **1372**         Turkey              Homozygous       c.1018G\>T              p.E340X           NM_004452.3                  ESRRB       Novel
  **794**          Turkey              Homozygous       c.508C\>A               p.H170N           NM_133261.2                  GIPC3       Novel
  **1356**         Turkey              Homozygous       c.508C\>A               p.H170N           NM_133261.2                  GIPC3       Novel
  **182**          Turkey              Homozygous       c.4480C\>T              p.R1494X          NM_144612.6                  LOXHD1      (Diaz-Horta 2012)^[@R4]^
  **779**          Turkey              Homozygous       c.2863G\>T              p.E955X           NM_144612.6                  LOXHD1      (Diaz-Horta 2012)^[@R4]^
  **303**          Turkey              Homozygous       c.628A\>T               p.K210X           NM_005709.3                  USH1C       Novel
  **994**          Iran                Homozygous       c.876+2delTA            splice            NM_005709.3                  USH1C       Novel
  **661**          Turkey              Homozygous       c.330T\>A               p.Y110X           NM_006383.3                  CIB2        Novel
  **262**          Turkey              Homozygous       c.2662C\>A              p.P888T           NM_080680.2                  COL11A2     (Chakchouk 2015)^[@R37]^
  **448**          Turkey              Homozygous       c.499C\>T               p.R167X           NM_001042702.3               DFNB59      (Collin 2007)^[@R38]^
  **908**          Turkey              Homozygous       c.102-1G\>A             splice            NM_014722.2                  FAM65B      (Diaz-Horta 2014)^[@R17]^
  **1289**         Turkey              Homozygous       c.2956A\>T              p.K986X           NM_032119.3                  GPR98       Novel
  **820**          Turkey              Homozygous       c.79C\>T                p.R27X            NM_001080476.2               GRXCR1      Novel
  **67**           Turkey              Homozygous       c.1498C\>T              p.R500X           NM_001038603.2               MARVELD2    (Riazuddin 2006)^[@R39]^
  **1364**         Turkey              Homozygous       c.1015C\>T              p.R339W           NM_004999.3                  MYO6        (Yang 2013)^[@R40]^
  **63**           Turkey              Homozygous       CNV                     CNV               NM_144672.3                  OTOA        (Bademci 2014)^[@R15]^
  **338**          Turkey              Homozygous       c.1430delT              p.V477EfsX25      NM_173591.3                  OTOGL       (Yariz 2012)^[@R16]^
  **1294**         Turkey              Homozygous       c.1108C\>T              p.R370X           NM_002906.3                  RDX         Novel
  **850**          Turkey              Homozygous       CNV                     CNV               NM_153700.2                  STRC        (Bademci 2014)^[@R15]^
  **1035**         Iran                Homozygous       c.5210A\>G              p.Y1737C          NM_005422.2                  TECTA       (Diaz-Horta 2012)^[@R4]^
  **7**            Turkey              Homozygous       c.705_709dupCCTGC       p.R237PfsX215     NM_001128228.2               TPRN        Novel
  **23**           Turkey              Homozygous       c.2335_2336delAG        p.R785SfsX50      NM_001039141.2               TRIOBP      (Diaz-Horta 2012)^[@R4]^
  **5**            Turkey              Homozygous       c.387_388insC           p.K130QfsX5       NM_173477.2                  USH1G       Novel

Families with compound heterozygous mutations are italicized.

###### Overview of mutation detection and parental consanguinity

  Countries         Number of Families   Reported Parental Consanguinity   Number of Homozygous Probands (consanguineous)   Number of Compound Heterozygous Probands (consanguineous)
  ----------------- -------------------- --------------------------------- ------------------------------------------------ -----------------------------------------------------------
  **Turkey**        101                  82                                67 (59)                                          5 (2)
  **Iran**          54                   31                                12 (10)                                          1 (1)
  **Ecuador**       2                    0                                 0                                                1 (0)
  **Mexico**        2                    0                                 0                                                1 (0)
  **Puerto Rico**   1                    0                                 0                                                1 (0)
